UK markets closed

Spyre Therapeutics, Inc. (SYRE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.69-2.86 (-8.05%)
As of 02:32PM EDT. Market open.
Full screen
Loading interactive chart…
  • PR Newswire

    Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

    Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women's Health, to its Board of Directors.

  • PR Newswire

    Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of inflammatory bowel disease ("IBD"), today announced its first quarter 2024 financial results and provided program and corporate updates.

  • PR Newswire

    Spyre Therapeutics Announces Grants of Inducement Awards

    Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 126,000 shares of common stock of Spyre to 4 non-executive empl